Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence

Kristin Banek, Mirza Lalani, Sarah G Staedke, Daniel Chandramohan, Kristin Banek, Mirza Lalani, Sarah G Staedke, Daniel Chandramohan

Abstract

Background: Increasing access to and targeting of artemisinin-based combination therapy (ACT) is a key component of malaria control programmes. To maximize efficacy of ACT and ensure adequate treatment outcomes, patient and caregiver adherence to treatment guidelines is essential. This review summarizes the current evidence base on ACT adherence, including definitions, measurement methods, and associated factors.

Methods: A systematic search of the published literature was undertaken in November 2012 and updated in April 2013. Bibliographies of manuscripts were also searched and additional references identified. Studies were included if they involved at least one form of ACT and reported an adherence measurement.

Results: The search yielded 1,412 records, 37 of which were found to measure adherence to ACT. Methods to measure adherence focused on self-report, pill counts and bioassays with varying definitions for adherence. Most studies only reported whether medication regimens were completed, but did not assess how the treatment was taken by the patient (i.e. timing, frequency and dose). Adherence data were available for four different ACT formulations: artemether-lumefantrine (AL) (range 39-100%), amodiaquine plus artesunate (AQ + AS) (range 48-94%), artesunate plus sulphadoxine-pyrimethamine (AS + SP) (range 39-75%) and artesunate plus mefloquine (AS + MQ) (range 77-95%). Association between demographic factors, such as age, gender, education and socio-economic status and adherence to ACT regimens was not consistent. Some evidence of positive association between adherence and patient age, caregiver education levels, drug preferences, health worker instructions, patient/caregiver knowledge and drug packaging were also observed.

Conclusions: This review highlights the weak evidence base on ACT adherence. Results suggest that ACT adherence levels varied substantially between study populations, but comparison between studies was challenging due to differences in study design, definitions, and methods used to measure adherence. Standardising methodologies for both self-report and bioassays used for evaluating adherence of different formulations across diverse contexts would improve the evidence base on ACT adherence and effectiveness; namely, specific and measurable definitions for adherence are needed for both methodologies. Additionally, further studies of the individual factors and barriers associated with non-adherence to ACT are needed in order to make informed policy choices and to improve the delivery of effective malaria treatment.

Figures

Figure 1
Figure 1
Treatment effectiveness pathway. This figure depicts each step along the pathway to malaria treatment effectiveness. At the top of the pathway are the health system factors such as choosing efficacious treatments such as ACT, improving access to those treatments and targeting treatments to those that need it most. The second half of the pathway depicts individual factors that can enhance or disrupt the effectiveness pathway such as provider compliance to treatment guidelines and patient/caregiver adherence to treatment regimens. Source: Original figure courtesy of Marcel Tanner, personal communication 2012 and manuscript published by, The malERA Consultative Group on Health Systems and Operational Research, A Research Agenda for Malaria Eradication: Health Systems and Operational Research. PLoS Med, 2011. 8(1): p. E1000397.
Figure 2
Figure 2
Systematic review process. Flow diagram (adapted from PRISMA) describing the systematic review of the literature on ACT adherence.

References

    1. WHO. World Malaria Report 2011. Geneva: World Health Organization; 2011.
    1. WHO. T3: Test. Treat. Track Initiative. Geneva: World Health Organization; 2012.
    1. WHO. Guidelines for the Treatment of Malaria. Second edn. Geneva: World Health Organization; 2010.
    1. Bosman A, Mendis KN. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg. 2007;77:193–197.
    1. WHO. World Malaria Report 2009. Geneva: World Health Organization; 2009.
    1. Laxminarayan R, Over M, Smith DL. Will a global subsidy of new antimalarials delay the emergence of resistance and save lives? Health Aff. 2006;25:325–336. doi: 10.1377/hlthaff.25.2.325.
    1. Matowe L, Adeyi O. The quest for universal access to effective malaria treatment: how can the AMFm contribute? Malar J. 2010;9:274. doi: 10.1186/1475-2875-9-274.
    1. Whitty CJM, Chandler C, Ansah E, Leslie T, Staedke SG. Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar J. 2008;7:S7. doi: 10.1186/1475-2875-7-S1-S7.
    1. WHO. The Use of Antimalarial Drugs. Geneva: World Health Organization; 2001.
    1. Yeung S, White NJ. How do patients use antimalarial drugs? A review of the evidence. Trop Med Int Health. 2005;10:121–138. doi: 10.1111/j.1365-3156.2004.01364.x.
    1. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–467. doi: 10.1056/NEJMoa0808859.
    1. Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ. 2004;82:935–939.
    1. Orton LC, Barnish G. Unit-dose packaged drugs for treating malaria. Cochrane Database Syst Rev. 2005;2:CD004614.
    1. Yeboah-Antwi K, Gyapong J, Asare I, Barnish G, Evans D, Adjei S. Impact of prepackaging antimalarial drugs on cost to patients and compliance with treatment. Bull World Health Organ. 2001;79:394–399.
    1. Reilley B, Abeyasinghe R, Pakianathar MV. Barriers to prompt and effective treatment of malaria in northern Sri Lanka. Trop Med Int Health. 2002;7:744–749. doi: 10.1046/j.1365-3156.2002.00919.x.
    1. Souares A, Lalou R, Sene I, Sow D, Le Hesran J-Y. Factors related to compliance to anti-malarial drug combination: example of amodiaquine/sulphadoxine-pyrimethamine among children in rural Senegal. Malar J. 2009;8:118. doi: 10.1186/1475-2875-8-118.
    1. Winstanley P, Ward S, Snow R, Breckenridge A. Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy. Clin Microbiol Rev. 2004;17:612–637. doi: 10.1128/CMR.17.3.612-637.2004.
    1. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074–1090. doi: 10.1016/S0149-2918(99)80026-5.
    1. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304. doi: 10.4065/mcp.2010.0575.
    1. Martin LR, Williams SL, Haskard KB, DiMatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1:189.
    1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497. doi: 10.1056/NEJMra050100.
    1. Turner BJ, Hecht FM. Improving on a coin toss to predict patient adherence to medications. Ann Intern Med. 2001;134:1004–1006. doi: 10.7326/0003-4819-134-10-200105150-00015.
    1. Twagirumukiza M, Kayumba PC, Kips JG, Vrijens B, Stichele RV, Vervaet C, Remon JP, Van Bortel ML. Evaluation of medication adherence methods in the treatment of malaria in Rwandan infants. Malar J. 2010;9:206. doi: 10.1186/1475-2875-9-206.
    1. Fungladda W, Honrado ER, Thimasarn K, Kitayaporn D, Karbwang J, Kamolratanakul P, Masngammueng R. Compliance with artesunate and quinine + tetracycline treatment of uncomplicated falciparum malaria in Thailand. Bull World Health Organ. 1998;76(Suppl 1):59–66.
    1. Le N, Pham T, Nguyen B, Dang C, Pham T, Le D. Efficacy and effectiveness of five day treatment of uncomplicated falciparum with artemisinin or artesunate in Vietnam. Southeast Asian J Trop Med Public Health. 1999;30:3–6.
    1. Na-Bangchang K, Congpuong K, Sirichaisinthop J, Suprakorb K, Karbwang J. Compliance with a 2 day course of artemether-mefloquine in an area of highly multi-drug resistant Plasmodium falciparum malaria. Br J Clin Pharmacol. 1997;43:639–642.
    1. Shwe T, Lwin M, Aung S. Influence of blister packaging on the efficacy of artesunate + mefloquine over artesunate alone in community-based treatment of non-severe falciparum malaria in Myanmar. Bull World Health Organ. 1998;76(Suppl 1):35–41.
    1. Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M, Lindegardh N, Singtoroj T, Ashley E, Lwin S. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet. 2006;367:2075–2085. doi: 10.1016/S0140-6736(06)68931-9.
    1. Yeung S, Socheat D, Van Damme W, Mills A, White N. Second International Conference of Improving Use of Medicines. Thailand: Chiang Mai; 2004. Artemisinin based combination therapy for malaria in Cambodia: How well is it being implemented.
    1. Depoortere E, Guthmann J-P, Sipilanyambe N, Nkandu E, Fermon F, Balkan S, Legros D. Adherence to the combination of sulphadoxine-pyrimethamine and artesunate in the Maheba refugee settlement, Zambia. Trop Med Int Health. 2004;9:62–67. doi: 10.1046/j.1365-3156.2003.01157.x.
    1. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P, Musabe J, Kyomugisha A, Guthmann J-P. Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am J Trop Med Hyg. 2004;71:525–530.
    1. Critical Appraisal Skills Programme (CASP): Appraising the Evidence. [ ]
    1. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–1457. doi: 10.1016/S0140-6736(07)61602-X.
    1. Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. STROBE Initiative: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18:805–835. doi: 10.1097/EDE.0b013e3181577511.
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869. doi: 10.1136/bmj.c869.
    1. Kabanywanyi AM, Lengeler C, Kasim P, King’eng’ena S, Schlienger R, Mulure N, Genton B. Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania. Malar J. 2010;9:48. doi: 10.1186/1475-2875-9-48.
    1. Lawford H, Zurovac D, O’Reilly L, Hoibak S, Cowley A, Munga S, Vulule J, Juma E, Snow RW, Allan R. Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts. Kenya. Malar J. 2011;10:281. doi: 10.1186/1475-2875-10-281.
    1. Mace KE, Mwandama D, Jafali J, Luka M, Filler SJ, Sande J, Ali D, Kachur SP, Mathanga DP, Skarbinski J. Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi. Clin Infect Dis. 2011;53:772–779. doi: 10.1093/cid/cir498.
    1. Ajayi IO, Browne EN, Bateganya F, Yar D, Happi C, Falade CO, Gbotosho GO, Yusuf B, Boateng S, Mugittu K, Cousens S, Nanyunja M, Pagnoni F. Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: A report from three study sites in sub-Saharan Africa. Malar J. 2008;7:190. doi: 10.1186/1475-2875-7-190.
    1. Ajayi IO, Browne EN, Garshong B, Bateganya F, Yusuf B, Agyei-Baffour P, Doamekpor L, Balyeku A, Munguti K, Cousens S, Pagnoni F. Feasibility and acceptability of artemisinin-based combination therapy for the home management of malaria in four African sites. Malar J. 2008;7:6. doi: 10.1186/1475-2875-7-6.
    1. Alba S, Hetzel MW, Goodman C, Dillip A, Liana J, Mshinda H, Lengeler C. Improvements in access to malaria treatment in Tanzania after switch to artemisinin combination therapy and the introduction of accredited drug dispensing outlets - a provider perspective. Malar J. 2010;9:164. doi: 10.1186/1475-2875-9-164.
    1. Chinbuah AM, Gyapong JO, Pagnoni F, Wellington EK, Gyapong M. Feasibility and acceptability of the use of artemether-lumefantrine in the Home-management of uncomplicated malaria in children 6–59 months old in Ghana. Trop Med Int Health. 2006;11:1003–1016. doi: 10.1111/j.1365-3156.2006.01654.x.
    1. Lemma H, Lofgren C, San Sebastian M. Adherence to a six-dose regimen of artemether-lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region. Ethiopia. Malar J. 2011;10:349. doi: 10.1186/1475-2875-10-349.
    1. Ogolla JO, Ayaya SO, Otieno CA. Levels of adherence to Coartem© in the routine treatment of un-complicated malaria in children aged below five years, in Kenya. Iran J Public Health. 2013;42:129–133.
    1. Rahman MM, Dondorp AM, Day NPJ, Lindegardh N, Imwong M, Faiz MA, Bangali AM, Kamal ATMM, Karim J, Kaewkungwal J, Singhasivanon P. Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Trans R Soc Trop Med Hyg. 2008;102:861–867. doi: 10.1016/j.trstmh.2008.05.022.
    1. Simba DO, Kakoko D, Tomson G, Premji Z, Petzold M, Mahindi M, Gustafsson LL. Adherence to artemether/lumefantrine treatment in children under real-life situations in rural Tanzania. Trans R Soc Trop Med Hyg. 2012;106:3–9. doi: 10.1016/j.trstmh.2011.09.006.
    1. Zaw Win T, Zaw L, Khin W, Khin L, Myitzu Tin O, Thar Tun K, Kyaw Zin T. Adherence to the recommended regimen of artemether-lumefantrine for treatment of uncomplicated falciparum malaria in Myanmar. Myanmar Health Sci Res J. 2012;24:48–53.
    1. Onyango EO, Ayodo G, Watsierah CA, Were T, Okumu W, Anyona SB, Raballah E, Okoth JM, Gumo S, Orinda GO. Factors associated with non-adherence to Artemisinin-based Combination Therapy (ACT) to malaria in a rural population from holoendemic region of western Kenya. BMC Infect Dis. 2012;12:143. doi: 10.1186/1471-2334-12-143.
    1. Barnes KI, Durrheim DN, Little F, Jackson A, Mehta U, Allen E, Dlamini SS, Tsoka J, Bredenkamp B, Mthembu DJ, White NJ, Sharp BL. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal. South Africa. PLoS Med. 2005;2:e330.
    1. Congpuong K, Bualombai P, Banmairuroi V, Na-Bangchang K. Compliance with a three-day course of artesunate-mefloquine combination and baseline anti-malarial treatment in an area of Thailand with highly multidrug resistant falciparum malaria. Malar J. 2010;9:43. doi: 10.1186/1475-2875-9-43.
    1. Kangwana BP, Kedenge SV, Noor AM, Alegana VA, Nyandigisi AJ, Pandit J, Fegan GW, Todd JE, Brooker S, Snow RW, Goodman CA. The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial. PLoS Med. 2011;8:e1000437. doi: 10.1371/journal.pmed.1000437.
    1. Meankaew P, Kaewkungwal J, Khamsiriwatchara A, Khunthong P, Singhasivanon P, Satimai W. Application of mobile-technology for disease and treatment monitoring of malaria in the. Malar J. 2010;9:237. doi: 10.1186/1475-2875-9-237.
    1. Watsierah CA, Jura WGZO, Raballah E, Kaseje D, Abong’o B, Ouma C. Knowledge and behaviour as determinants of anti-malarial drug use in a peri-urban population from malaria holoendemic region of western Kenya. Malar J. 2011;10:99. doi: 10.1186/1475-2875-10-99.
    1. Yeung S, Van Damme W, Socheat D, White NJ, Mills A. Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malar J. 2008;7:96. doi: 10.1186/1475-2875-7-96.
    1. Achan J, Tibenderana JK, Kyabayinze D, Wabwire Mangen F, Kamya MR, Dorsey G, D’Alessandro U, Rosenthal PJ, Talisuna AO. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ. 2009;339:b2763. doi: 10.1136/bmj.b2763.
    1. Beer N, Ali AS, Rotllant G, Abass AK, Omari RS, Al-mafazy A-wH, Bjorkman A, Kallander K. Adherence to artesunate-amodiaquine combination therapy for uncomplicated malaria in children in Zanzibar, Tanzania. Trop Med Int Health. 2009;14:766–774. doi: 10.1111/j.1365-3156.2009.02289.x.
    1. Cohen JL, Yavuz E, Morris A, Arkedis J, Sabot O. Do patients adhere to over-the-counter artemisinin combination therapy for malaria? evidence from an intervention study in Uganda. Malar J. 2012;11:83. doi: 10.1186/1475-2875-11-83.
    1. Depoortere E, Salvador ETC, Stivanello E, Bisoffi Z, Guthmann JP. Adherence to a combination of artemether and lumefantrine (Coartem) in Kajo Keji, southern Sudan. Ann Trop Med Parasitol. 2004;98:635–637. doi: 10.1179/000349804225021271.
    1. Dunyo S, Sirugo G, Sesay S, Bisseye C, Njie F, Adiamoh M, Nwakanma D, Diatta M, Janha R, Sisay Joof F, Temple B, Snell P, Conway D, Walton R, Cheung YB, Milligan P. Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia. PLoS One. 2011;6:e17371. doi: 10.1371/journal.pone.0017371.
    1. Faucher JF, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B, Houzé P, Kossou H, Amedome H, Massougbodji A. Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated Plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial. J Infect Dis. 2009;200:57–65. doi: 10.1086/599378.
    1. Gerstl S, Dunkley S, Mukhtar A, Baker S, Maikere J. Successful introduction of artesunate combination therapy is not enough to fight malaria: results from an adherence study in Sierra Leone. Trans R Soc Trop Med Hyg. 2010;104:328–335. doi: 10.1016/j.trstmh.2009.12.008.
    1. Kachur SP, Khatib RA, Kaizer E, Fox SS, Abdulla SM, Bloland PB. Adherence to antimalarial combination therapy with sulfadoxine-pyrimethamine and artesunate in rural Tanzania. Am J Trop Med Hyg. 2004;71:715–722.
    1. Kalyango JN, Rutebemberwa E, Karamagi C, Mworozi E, Ssali S, Alfven T, Peterson S. High adherence to antimalarials and antibiotics under integrated community case management of illness in children less than five years in eastern Uganda. PLoS One. 2013;8:e60481. doi: 10.1371/journal.pone.0060481.
    1. Mubi M, Janson A, Warsame M, Mårtensson A, Källander K, Petzold MG, Ngasala B, Maganga G, Gustafsson LL, Massele A. Malaria rapid testing by community health workers is effective and safe for targeting malaria treatment: randomised cross-over trial in Tanzania. PLoS One. 2011;6:e19753. doi: 10.1371/journal.pone.0019753.
    1. Ratsimbasoa A, Ravony H, Vonimpaisomihanta J-A, Raherinjafy R, Jahevitra M, Rapelanoro R, Rakotomanga JDDM, Malvy D, Millet P, Menard D. Compliance, safety, and effectiveness of fixed-dose artesunate-amodiaquine for presumptive treatment of non-severe malaria in the context of home management of malaria in Madagascar. Am J Trop Med Hyg. 2012;86:203–210. doi: 10.4269/ajtmh.2012.11-0047.
    1. Asante KP, Owusu R, Dosoo D, Awini E, Adjei G, Etego SA, Chandramohan D, Owusu-Agyei S. Adherence to artesunate-amodiaquine therapy for uncomplicated malaria in rural Ghana: a randomised trial of supervised versus unsupervised drug administration. J Trop Med. 2009;2009:529583.
    1. Bell DJ, Wootton D, Mukaka M, Montgomery J, Kayange N, Chimpeni P, Hughes DA, Molyneux ME, Ward SA, Winstanley PA, Lalloo DG. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar J. 2009;8:204. doi: 10.1186/1475-2875-8-204.
    1. Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, Bergqvist Y, Gil JP, Premji Z, Martensson A. Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study. Malar J. 2011;10:64. doi: 10.1186/1475-2875-10-64.
    1. Simba DO, Warsame M, Kimbute O, Kakoko D, Petzold M, Tomson G, Premji Z, Gomes M. Factors influencing adherence to referral advice following pre-referral treatment with artesunate suppositories in children in rural Tanzania. Trop Med Int Health. 2009;14:775–783. doi: 10.1111/j.1365-3156.2009.02299.x.
    1. Barnes K. Preventing antimalarial resistance with artemisinin-based combination therapy. CME. 2008;22:205.
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74. doi: 10.1097/00005650-198601000-00007.
    1. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37:113–124. doi: 10.1016/S0738-3991(98)00107-4.
    1. Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ. 2011;89:632–639. doi: 10.2471/BLT.11.086462.
    1. Checchi F, Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor WR, Guthmann JP. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar J. 2006;5:59. doi: 10.1186/1475-2875-5-59.
    1. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet. 2005;365:1467–1473. doi: 10.1016/S0140-6736(05)66416-1.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe